Samuel Moser
Hoffmann-La Roche
35 Papers
325 Citations
Samuel Moser is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Antibody & Antibody-dependent cell-mediated cytotoxicity. The author has an hindex of 14, co-authored 35 publications.
Chat about Author
Papers
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
Ekkehard Mössner,Peter Brünker,Samuel Moser,Ursula Püntener,Carla Schmidt,Sylvia Herter,Roger Grau,Christian Gerdes,Adam Nopora,Erwin van Puijenbroek,Claudia Ferrara,Peter Sondermann,Christiane Jäger,Pamela Strein,Georg Fertig,Thomas Friess,Christine Schüll,Sabine Bauer,Joseph Dal Porto,Christopher Del Nagro,Karim Dabbagh,Martin J. S. Dyer,Sibrand Poppema,Christian Klein,Pablo Umana +24 more
TL;DR: In human lymphoma xenograft models, GA101 exhibits superior antitumor activity, resulting in the induction of complete tumor remission and increased overall survival and in nonhuman primates, GA 101 demonstrates superior B cell-depleting activity in lymphoid tissue, including in lymph nodes and spleen.
965
Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II
TL;DR: The results indicate that chimeric GnT‐III can compete even more efficiently against the endogenous core α1,6‐fucosyltransferase (α1, 6‐FucT) and Golgi α‐mannosidase II (ManII) leading to higher proportions of bisected non‐fukosylated hybrid glycans (“Glyco‐1” antibody).
370
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment
Anja Seckinger,Jose Antonio Delgado,Samuel Moser,Laura Moreno,Brigitte Neuber,Anna Luise Grab,Susanne Lipp,Juana Merino,Felipe Prosper,Martina Emde,Camille Delon,Melanie Latzko,Reto Gianotti,Remo Lüoend,Ramona Murr,Ralf Hosse,Lydia Jasmin Harnisch,Marina Bacac,Tanja Fauti,Christian Klein,Aintzane Zabaleta,Jens Hillengass,Elisabetta Ada Cavalcanti-Adam,Anthony D. Ho,Michael Hundemer,Jesús F. San Miguel,Klaus Strein,Pablo Umana,Dirk Hose,Bruno Paiva,Minh Diem Vu +30 more
TL;DR: An IgG-based BCMA-T cell bispecific antibody (EM801) was constructed and showed that it increased CD3+ T-cell/myeloma cell crosslinking, followed by CD4+/CD8+ T cell activation, and secretion of interferon-γ, granzyme B, and perforin, which is CD4 and CD8 T cell mediated.
294
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.
Christian Klein,Inja Waldhauer,Nicolini Valeria G,Anne Freimoser-Grundschober,Tapan K. Nayak,Danielle J. Vugts,Claire Dunn,Marije Bolijn,Jörg Benz,Martine Stihle,Sabine Lang,Michaele Roemmele,Hofer Thomas U,Erwin van Puijenbroek,David Wittig,Samuel Moser,Oliver Ast,Peter Brünker,Ingo H. Gorr,Sebastian Neumann,Maria Cristina De Vera Mudry,Heather Hinton,Flavio Crameri,Jose Saro,Stefan Evers,Christian Gerdes,Marina Bacac,Guus A.M.S. van Dongen,Ekkehard Moessner,Pablo Umana +29 more
TL;DR: Preclinical data support the ongoing clinical investigation of the cergutuzumab amunaleukin immunocytokine with abolished CD25 binding for the treatment of CEA-positive solid tumors in combination with PD-L1 checkpoint blockade and ADCC competent antibodies.
245
Patent
Bispecific antibodies against cd3epsilon and bcma
Minh Diem Vu,Klaus Strein,Oliver Ast,Marina Bacac,Lydia Jasmin Hanisch,Tanja Fauti,Anne Freimoser-Grundschober,Ralf Hosse,Christian Klein,Ekkehard Moessner,Samuel Moser,Ramona Murr,Pablo Umana,Sabine Jung-Imhof,Stefan Klostermann,Michael Molhoj,Joerg Thomas Regula,Wolfgang Schaefer +17 more
- 03 Aug 2015
TL;DR: In this paper, bispecific antibodies against ROR1 and CD3, their manufacture and use are described. But their use is limited to the use of immunoglobulin-based drugs.
63